The study was done from a U.S. dollar view, but the council said its findings are applicable to other foreign investments where higher borrowing costs make traditional currency hedging expensive.
This morning, Pfizer released the top-line data from its study of tofacitinib, the experimental arthritis drug most Wall Street analysts view as its most important experimental drug.
